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ADIOS ADJUVANT
COMBINATION IMMUNOTHERAPY FOR PEDIATRIC ACUTE
LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS
Arleigh Wood
Longwood University Department of Biological and Environmental Sciences

INTRODUCTION

EXPECTED RESULTS
• Kymriah®
• Around 60% of pediatric
cancers cases are Acute
Lymphoblastic Leukemia
(Lee, et al. 2016).
• Chemotherapy
was once believed to be a
cure for multiple cancers
(ACS, 2020).

Figure 1. Immunotherapies has less side effects and
prolonged protection from chemotherapies (ACS, 2020).

• Chemotherapy has intense side effects with less prolonged protection
compared to immunotherapies (Figure 1).
• Am immunological approach to the treatment of cancer is less traumatic to
the body and yields higher remission rates than previous adjuvant therapies.
• Common immunotherapies include monoclonal antibodies (A), checkpoint
blockade inhibitors (B), and CAR T cell therapy (C) (Frey, 2019).
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• 75% Remission Rate for all
patients
• 19 months until remission is
reached
• 50% of patients will have
event-free survival
• In remission for 61 months
before more treatment is
needed (average).

• Blinatumomab
• Over 50% will achieve
complete remission
• Only 4% incidence of
CRS (Cytokine Release
Syndrome)
A•

HYPOTHESIS

Table 1. The responses in a test group of 38 pediatric
leukemia patients in secondary relapse after steady dosage of
Kymriah for 48 hours and 14 days of no treatment (Boyiadzis,
2018).

14% of test group
B
achieved MRD (Minimum
Disease Response)

C

D

E

F

Table 2. Responses of a test group of 44-49 patients to a
maximum dose of 15 μg/m2/kg Blinatumomab. Responses
differed based on trial phase and relapse phase.

IMPLICATIONS

If two successful independent immunotherapies, Kymriah® and Blinatumomab,
are combined and administered via repeated intravenous injections, then patients
• Combining two successful immunotherapies is likely to result in a high
with Acute Lymphoblastic Leukemia will achieve higher rates of remission than if
success rate (near 100%).
only one immunotherapy was administered.

• In most studies, side effects of immunotherapies were incomparable
to adjuvant therapies (1-4% incidence).

PROPOSED METHODS
• Test Group of 30 children with relapsed ALL will recieve simultaneous
injections of Kymriah and Blinatumomab

• Cost of T cell therapies is a major complication of the availability of
this research ($800K-$1M).
• Cytokine release syndrome is a constant battle for immunotherapies
that is being heavily researched in clinical trials.

Kymriah®

• The quality of life of pediatric patients will be significantly improved
during treatment.
48-hour intravenous
administration
of
G
3.1 × 106 cells/kg CAR
T cells

Patient receives
no treatment for
14 days

Evaluate
response after 2
weeks of rest,
Repeat

Monitor for 2-3
days a week

The goal of the experiment is to take two successful treatments for ALL with
minimum 50% remission rates, Blinatumomab and Kymriah, and combine
them to create a non-invasive, FDA approved immunotherapy with a near
100% remission rate within 10 years.
T Cell Count

FUTURE STUDIES
• Begin in vitro studies to test for CRS and side effects of combination of
therapies

Blinatumomab

24 hours intravenous
administration,
15 μg/m2/kg

PROJECT AIM

• Progress to in vivo studies in mice to test how drugs interact in circulatory
system of model organism with ALL

T Cell Count

Evaluate for
repeat trial

No
treatment
for 14 days

Quantify antileukemia activity
via cell lysis of
ALL

• Eventually progress to a series of clinical trials to get FDA approval
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